GlaxoSmithKline PLC
LSE:GSK

Watchlist Manager
GlaxoSmithKline PLC Logo
GlaxoSmithKline PLC
LSE:GSK
Watchlist
Price: 1 342 GBX 2.48% Market Closed
Market Cap: 54.7B GBX
Have any thoughts about
GlaxoSmithKline PLC?
Write Note

GlaxoSmithKline PLC
Cash Taxes Paid

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

GlaxoSmithKline PLC
Cash Taxes Paid Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Taxes Paid CAGR 3Y CAGR 5Y CAGR 10Y
GlaxoSmithKline PLC
LSE:GSK
Cash Taxes Paid
ÂŁ1.5B
CAGR 3-Years
-3%
CAGR 5-Years
2%
CAGR 10-Years
1%
AstraZeneca PLC
LSE:AZN
Cash Taxes Paid
$2.6B
CAGR 3-Years
17%
CAGR 5-Years
22%
CAGR 10-Years
13%
Verona Pharma PLC
NASDAQ:VRNA
Cash Taxes Paid
$279k
CAGR 3-Years
-71%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Indivior PLC
LSE:INDV
Cash Taxes Paid
$44m
CAGR 3-Years
122%
CAGR 5-Years
N/A
CAGR 10-Years
-5%
Hikma Pharmaceuticals PLC
LSE:HIK
Cash Taxes Paid
$99m
CAGR 3-Years
-9%
CAGR 5-Years
8%
CAGR 10-Years
-1%
Dechra Pharmaceuticals PLC
LSE:DPH
Cash Taxes Paid
ÂŁ27.4m
CAGR 3-Years
29%
CAGR 5-Years
19%
CAGR 10-Years
13%
No Stocks Found

GlaxoSmithKline PLC
Glance View

Market Cap
54.7B GBX
Industry
Pharmaceuticals

GlaxoSmithKline PLC (GSK) is a global healthcare giant rooted in extensive research and development, dedicated to improving the health and well-being of people around the world. Founded in 2000 through a merger of Glaxo Wellcome and SmithKline Beecham, GSK has built a diverse portfolio that spans pharmaceuticals, vaccines, and consumer healthcare. With a strong emphasis on innovation, GSK invests heavily in R&D, focusing on tackling significant health challenges such as infectious diseases, oncology, and respiratory ailments. The company’s robust pipeline showcases its commitment to advancing medical science, promising both potential breakthroughs for patients and lucrative prospects for investors. In recent years, GSK has taken strategic steps to simplify its business model, including the spin-off of its consumer healthcare segment into a separate entity. This maneuver has allowed GSK to concentrate on its core pharmaceutical and vaccine operations, optimizing its resources towards high-growth areas. As the world faces ongoing health crises and the demand for vaccines, particularly following the COVID-19 pandemic, GSK is well-positioned to capitalize on its innovation and solid market presence. For investors, GSK's balance sheet reflects a stable dividend, attractive growth prospects, and a commitment to sustainable practices, fostering confidence that it remains a compelling choice in the ever-evolving healthcare landscape.

GSK Intrinsic Value
2 400.47 GBX
Undervaluation 44%
Intrinsic Value
Price

See Also

What is GlaxoSmithKline PLC's Cash Taxes Paid?
Cash Taxes Paid
1.5B GBP

Based on the financial report for Jun 30, 2024, GlaxoSmithKline PLC's Cash Taxes Paid amounts to 1.5B GBP.

What is GlaxoSmithKline PLC's Cash Taxes Paid growth rate?
Cash Taxes Paid CAGR 10Y
1%

Over the last year, the Cash Taxes Paid growth was 12%. The average annual Cash Taxes Paid growth rates for GlaxoSmithKline PLC have been -3% over the past three years , 2% over the past five years , and 1% over the past ten years .

Back to Top